{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:34Z","timestamp":1740120094737,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12185-021-03278-5","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:03:41Z","timestamp":1642809821000},"page":"508-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution"],"prefix":"10.1007","volume":"115","author":[{"given":"Kei","family":"Hayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sosei","family":"Okina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaeko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhsaku","family":"Kanoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8438-2186","authenticated-orcid":false,"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,22]]},"reference":[{"key":"3278_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic Syndromes. N Engl J Med. 2020;383:1358\u201374.","journal-title":"N Engl J Med"},{"key":"3278_CR2","unstructured":"WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017."},{"key":"3278_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3278_CR4","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L Malcovati","year":"2005","unstructured":"Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594\u2013603.","journal-title":"J Clin Oncol"},{"key":"3278_CR5","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338\u201347.","journal-title":"Lancet Oncol"},{"key":"3278_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140\u201351.","journal-title":"N Engl J Med"},{"key":"3278_CR7","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/sj.leu.2401556","volume":"13","author":"A Matsuda","year":"1999","unstructured":"Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Murohashi I, Bessho M, et al. New system for assessing the prognosis of refractory anemia patients. Leukemia. 1999;13:1727\u201334.","journal-title":"Leukemia"},{"key":"3278_CR8","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1182\/blood-2002-03-0947","volume":"101","author":"T Matsushima","year":"2003","unstructured":"Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin Y, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003;101:3386\u201390.","journal-title":"Blood"},{"key":"3278_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.leukres.2018.08.022","volume":"73","author":"Y Miyazaki","year":"2018","unstructured":"Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole F, et al. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: analysis from the International Working Group for Prognosis of MDS. Leuk Res. 2018;73:51\u20137.","journal-title":"Leuk Res"},{"key":"3278_CR10","first-page":"499","volume":"7","author":"K Toyama","year":"1993","unstructured":"Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia. 1993;7:499\u2013508.","journal-title":"Leukemia"},{"key":"3278_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12185-017-2250-0","volume":"106","author":"H Kawabata","year":"2017","unstructured":"Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, et al. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. Int J Hematol. 2017;106:375\u201384.","journal-title":"Int J Hematol"},{"key":"3278_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","volume":"24","author":"U Germing","year":"2000","unstructured":"Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983\u201392.","journal-title":"Leuk Res"},{"key":"3278_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241\u20137.","journal-title":"Leukemia"},{"key":"3278_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136:157\u201370.","journal-title":"Blood"},{"key":"3278_CR15","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3324\/haematol.13405","volume":"93","author":"GJ Mufti","year":"2008","unstructured":"Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93:1712\u20137.","journal-title":"Haematologica"},{"key":"3278_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12185-018-2551-y","volume":"108","author":"N Shingai","year":"2018","unstructured":"Shingai N, Harada Y, Iizuka H, Ogata Y, Doki N, Ohashi K, et al. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes. Int J Hematol. 2018;108:598\u2013606.","journal-title":"Int J Hematol"},{"key":"3278_CR17","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","volume":"118","author":"L Malcovati","year":"2011","unstructured":"Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood. 2011;118:6239\u201346.","journal-title":"Blood"},{"key":"3278_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/jcp.36.5.566","volume":"36","author":"S Juneja","year":"1983","unstructured":"Juneja S. Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol. 1983;36:566\u20139.","journal-title":"J Clin Pathol"},{"key":"3278_CR19","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"3278_CR20","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.3324\/haematol.2016.156844","volume":"102","author":"P Martin-Cabrera","year":"2017","unstructured":"Martin-Cabrera P, Jeromin S, Perglerov\u00e0 K, Haferlach C, Kern W, Haferlach T. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia. Haematologica. 2017;102:e125\u20138.","journal-title":"Haematologica"},{"key":"3278_CR21","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1182\/bloodadvances.2019000518","volume":"3","author":"G Berger","year":"2019","unstructured":"Berger G, Gerritsen M, Yi G, Koorenhof-Scheele TN, Kroeze LI, Stevens-Kroef M, et al. Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. Blood Adv. 2019;3:3111\u201322.","journal-title":"Blood Adv"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03278-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03278-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03278-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:04:18Z","timestamp":1648667058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03278-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,22]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3278"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03278-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,1,22]]},"assertion":[{"value":"29 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.K reports personal fees from Novartis Pharma K.K., Bristol-Myers Squibb, Ltd., Kyowa Kirin Co., Ltd. and Nippon Shinyaku Co. related to the submitted work. S.O reports personal fees from Novartis Pharma K.K., Bristol-Myers Squibb, Ltd., Kyowa Kirin Co., Ltd. and Nippon Shinyaku Co. related to the submitted work. Y.K. reports personal fees from AbbVie Inc. related to the submitted work. T.S. reports personal fees from Novartis Pharma K.K., Bristol-Myers Squibb, Ltd; grants and personal fees from AbbVie Inc., Kyowa Kirin Co., Ltd. and Nippon Shinyaku Co. related to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}